SecurityEANRF / Eastmain Resources Inc. (27743M106)
Latest Market Date2017-03-06
Short Volume500
Market Volume 39,900
Short Percent 1%

Short Interest and Volume

EANRF / Eastmain Resources Inc. short volume is shown in the following chart. Short Volume is a data set that can be used to understand investor sentiment. When an investor makes a short sale, they do so with the belief that a security will decline in price. If the short sale volume increases as a percentage of the total volume, then that suggests a bearish (negative) sentiment by the market. If short sale volume decreases as a percentage of total volume, then that suggests a bullish (positive) sentiment.

Short Volume
Total number of short shares traded on the major US markets each day
Short Percent
Total number of short shares traded divided by the total shares traded each day
Short Interest
Total number of open short positions of a security, divided by the total float (not shown)
Short Squeeze
When a company with a high degree of short interest increases in price, which forces short sellers to "cover" their short interest buy buying actual shares, which in turn drives the price up even further.

Note that Short Percent on this page is not the same as Short Interest. Short Interest is a measure of the number of open short positions of a security, divided by the total float. Short Percent is the daily short volume divided by the total volume. Short Interest is not available for this security at this time.

Market Date Total Volume Short Volume Short Percent
2017-03-06 39,900 500 1.25
2017-03-03 24,600 8,000 32.52
2017-03-02 67,600 12,886 19.06
2017-03-01 64,700 32,000 49.46
2017-02-28 383,600 141,950 37.00
2017-02-27 80,000 14,258 17.82
2017-02-24 60,200 44,740 74.32
2017-02-23 56,700 3,243 5.72
2017-02-22 54,200 8,000 14.76
2017-02-17 43,200 9,650 22.34

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: 27743M106